Lucatumumab
| Drug Information | |||
|---|---|---|---|
| Image | |||
| Identifiers
CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL |
Chemical Data
C H N O Molecular Weight | ||
Lucatumumab is an experimental monoclonal antibody designed for the treatment of cancer. It targets CD40, a co-stimulatory protein found on the surface of many immune system cells as well as some cancer cells. Lucatumumab is being investigated for its potential use in the treatment of various types of cancers, including multiple myeloma, non-Hodgkin lymphoma, and chronic lymphocytic leukemia.
Mechanism of Action[edit | edit source]
Lucatumumab works by binding to the CD40 molecule on the surface of tumor cells and immune cells. This binding can lead to the activation of antitumor immune responses and may also directly induce apoptosis (programmed cell death) in tumor cells. The CD40 receptor is an important player in the activation of both innate and adaptive immune responses, making it a promising target for cancer therapy.
Clinical Trials[edit | edit source]
Lucatumumab has been evaluated in several clinical trials. Early-phase trials have assessed its safety, tolerability, and preliminary efficacy in patients with various hematologic malignancies. The results from these trials have provided insights into the optimal dosing schedules and potential side effects, which include infusion reactions and cytokine release syndrome.
Development and Regulatory Status[edit | edit source]
As of the last update, Lucatumumab is still in the investigational stages and has not yet received approval from regulatory bodies such as the Food and Drug Administration (FDA) in the United States. Its development is being monitored by researchers and clinicians who are exploring its full potential and safety profile in a broader range of cancer types.
Potential Impact and Future Directions[edit | edit source]
If successful, Lucatumumab could offer a new therapeutic option for patients with cancers that express CD40. Ongoing research and future clinical trials will determine its place in cancer therapy, particularly in combination with other therapeutic agents like chemotherapy, radiotherapy, and other immunotherapies.
See Also[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
